Loading stock…

Omeros Corporation (OMER) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Omeros Corporation

OMERMarket cap $1.36BPrice $18.8

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops drugs targeting rare diseases and complement-mediated conditions, betting big on narsoplimab for a bone marrow transplant complication with zero approved treatments. A tiny biotech chasing a first-in-class FDA approval that could redefine its future overnight.

In Bastion Portfolios?

52W Return+131%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)na–

Rev CAGR (3y)na–

Rev CAGR (5y)na–

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+154%10

EPS Growth Y+3-1%3

Quality

Margins

EBIT Margin-190%1

Net Income Margin325%10

Free Cash Flow Margin-179%1

Debt

Net Debt/EBITDAna–

Efficiency

ROEna–

ROA51%10

Earnings Stability22

GEAR+VERY WEAK3

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)127

P/E Ratio (Forward 3y)79

P/BVna–

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwd5791

Yield

Free Cash Flow Yield-5.1%1

Dividend Yieldna–

Momentum

Short term

1 month return-2%7

3 month return+83%10

YTD return+9%6

Mid term

Price vs 52wHigh88%8

1 year return+327%10

Long term

3 year return+577%10

5 year return+180%9

Risk Shield

Price Risk

Beta1.32

Volatility136%1

Free Cash Flow

Free Cash Flow Margin-179%1

Free Cash Flow Yield-5.1%1

Quality

ROCE-47%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

OMEROmeros

Revenue FY18$30M

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+154%10

EPS growth, FY28E-1%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 0%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+83%10

YTD return+9%6

MID & LONG-TERM▾SCORE

% of 52-week high88%8

1-year return+327%10

3-year return+577%10

5-year return+180%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +577% over three years and +180% over five, ahead of 90% of the market.

It's up 327% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-2%) and over three months (+83%).

WATCH

Returns sit at the market level so far this year (+9%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Omeros Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

OMEROmeros

Revenue FY18$30M

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+154%10

EPS growth, FY28E-1%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 0%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+83%10

YTD return+9%6

MID & LONG-TERM▾SCORE

% of 52-week high88%8

1-year return+327%10

3-year return+577%10

5-year return+180%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +577% over three years and +180% over five, ahead of 90% of the market.

It's up 327% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-2%) and over three months (+83%).

WATCH

Returns sit at the market level so far this year (+9%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Omeros Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community